TOP NEWS: GlaxoSmithKline Notes Positive Study Of HIV Two-Drug Regimen
(Alliance News) - GlaxoSmithKline PLC on Wednesday noted that the Tango study of a dolutegravir plus lamivudine two-drug regimen in HIV-1 met its primary endpoint.The phase 3 Tango study a
Read more